{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020075","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.286138+00:00","generated_at":"2026-06-15T06:40:53.012186+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Finch Therapeutics Q1 net loss $63.9M on impairment charges; new CEO/CFO","bullets":["Net loss of $63.9M in Q1 2023 vs $24.6M in Q1 2022; includes $32.9M IPR&D impairment and $13.1M long-lived asset impairment.","Cash and equivalents $41.7M as of Mar 31, 2023; expects to fund operations into 2025.","Clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 in ulcerative colitis; topline data expected in 2025.","Executive leadership transition: Matthew Blischak to become CEO, Lance Thibault to become CFO effective May 16, 2023.","Safety analysis from discontinued PRISM4 trial showed no drug-related serious adverse events among 19 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020075","json":"https://secwatch.observer/filing/0000950170-23-020075.json","markdown":"https://secwatch.observer/filing/0000950170-23-020075.md","text":"https://secwatch.observer/filing/0000950170-23-020075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/0000950170-23-020075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/fnch-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:40:53.012186+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd3b8432dd5afddb88d6bb616350ae9c6b09a892","claim":"Finch Therapeutics Group, Inc. reported first quarter of 2023 results: net income net loss of $63.9 million.","evidence_excerpt":"Finch reported a net loss of $63.9 million for the first quarter of 2023, compared to a net loss of $24.6 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733257/000095017023020075/0000950170-23-020075-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Net income","value":"net loss of $63.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}